Article

## Structure, Absolute Configuration, and antiproliferative activity of abietane and icetexane diterpenoids from *Salvia ballotiflora*

Baldomero Esquivel <sup>1,</sup> \*, Celia Bustos-Brito <sup>1</sup>, Mariano Sánchez-Castellanos <sup>2</sup>, Antonio Nieto-Camacho <sup>1</sup>, Teresa Ramírez-Apan <sup>1</sup>, Pedro Joseph-Nathan <sup>3</sup>, and Leovigildo Quijano <sup>1,\*</sup>

- <sup>1</sup> Instituto de Química, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Mexico City., 04510 México; <u>baldo@unam.mx</u> (B.E.); <u>bustosbritocelia@comunidad.unam.mx</u> (C.B.-B); <u>anieto@unam.mx</u> (A.N), <u>mtrapan@unam.mx</u> (T.R.-A). <u>guijano@unam.mx</u> (Q.L.).
- <sup>2</sup> Facultad de Química, Universidad Nacional Autónoma de México, Circuito Exterior, Ciudad Universitaria, Mexico City., 04510 México; <u>msanchezcastellanos@gmail.com</u> (M. S.-C).
- <sup>3</sup> Departamento de Química, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Apartado 14-740, México, Mexico City, 07000 México; pjoseph@nathan.cinvestav.mx (P.J.-N).
- \* Correspondence: quijano@unam.mx; Tel.:+52-55-5622-4411

## **Supporting Information**

## **Table of Contents**

Figure S1. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 1 Figure S2. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 1 Figure S3. COSY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 1 Figure S4. HMBC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 1 Figure S5. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 1 Figure S6. NOESY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 1 Figure S7. HR-DART-MS of 1 Figure S8. 1H NMR (CDCl3, 700 MHz) spectrum of 2 Figure S9. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 2 Figure S10. COSY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 2 Figure S11. HMBC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 2 Figure S12. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 2 Figure S13. NOESY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 2 Figure S14. HR-DART-MS of 2 Figure S15. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 3 Figure S16. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 3 Figure S17. COSY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 3 Figure S18. HMBC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 3 Figure S19. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 3 Figure S20. NOESY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 3 Figure S21. HR-DART-MS of 3 Figure S22. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 4 Figure S23. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 4 Figure S24. COSY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 4 Figure S25. HMBC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 4 Figure S26. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 4 Figure S27. NOESY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 4 Figure S28. HR-DART-MS of 4 Figure S29. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 5 Figure S30. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 5 Figure S31. COSY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 5 Figure S32. HMBC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 5 Figure S33. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 5 Figure S34. NOESY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 5 Figure S35. HR-DART-MS of 5 Figure S36. 1H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 6 Figure S37. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 6 Figure S38. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 6 Figure S39. 1H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 7 Figure S40. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 7 Figure S41. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 7 Figure S42. 1H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 9

Figure S43. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 9
Figure S44. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 9
Figure S45. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 11
Figure S46. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 11
Figure S47. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 11
Figure S48. Primary screening of compounds 3, 4, 6 - 8, 10 on antiproliferative activity at concentration of 50.0 μM.



Figure S1. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 1



Figure S2. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 1



Figure S3. COSY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 1



Figure S4. HMBC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 1.



Figure S5. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 1



Figure S6. NOESY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 1



Figure S7. HR-DART-MS of 1



Figure S8. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 2



Figure S9. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 2



Figure S10. COSY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 2



Figure S11. HMBC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 2



Figure S12. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 2



Figure S13. NOESY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 2



Figure S14. HR-DART-MS of 2



Figure S15. 1H NMR (CDCl3, 700 MHz) spectrum of 3



Figure S16. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 3



Figure S17. COSY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 3



Figure S18. HMBC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 3



Figure S19. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 3



Figure S20. NOESY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 3



Figure S21. HR-DART-MS of 3



Figure S22. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 4



Figure S23. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 4



Figure S24. COSY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 4



Figure S25. HMBC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 4



Figure S26. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 4



Figure S27. NOESY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 4



Mass	Intensity	Calc. Mass	(mmu)	(ppm)	Possible Formula	Unsaturation Number
361.16436	63640.89	361.16511	-0.76	-2.09	<sup>12</sup> C <sub>20</sub> 1H <sub>25</sub> 16O <sub>6</sub>	8.5

Figure S28. HR-DART-MS of 4



Figure S29. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 5



Figure S30. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 5



Figure S31. COSY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 5



Figure S32. HMBC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 5



Figure S33. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 5



Figure S34. NOESY NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 5



Mass	Intensity	Calc. Mass	Mass Difference (mmu)	Mass Difference (ppm)	Possible Formula	Unsaturation Number
375.21725	125046.05	375.21715	0.10	0.27	<sup>12</sup> C <sub>22</sub> <sup>1</sup> H <sub>31</sub> <sup>16</sup> O <sub>5</sub>	7.5

Figure S35. HR-DART-MS of 5



Figure S36. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 6



Figure S37. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 6



Figure S38. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 6



Figure S39. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 7



Figure S40. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 7



Figure S41. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 7



Figure S42. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 9



Figure S43. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 9



Figure S44. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 9



Figure S45. 1H NMR (CDCl3, 700 MHz) spectrum of 11



Figure S46. <sup>13</sup>C NMR (CDCl<sub>3</sub>, 175 MHz) spectrum of 11



Figure S47. HSQC NMR (CDCl<sub>3</sub>, 700 MHz) spectrum of 11

Compound	Antiproliferative activity (%)						
	U251	PC-3	K562	HCT-15	MCF-7	SKLU-1	FGH
3*	65.4	34.2	48.6	33.4	NC	64.5	12.4
4	100	80.3	100	76.7	99.0	96.9	87.0
6*	98.4	82.3	76.4	85.6	51.3	100	46.5
7	10.1	17.8	63.2	26.8	62.6	46.5	NC
8	35.8	39.6	83.1	29.0	71.6	52.9	NC
10	NC	NC	NC	NC	14.7	11.8	NT
Adriamicyn 0.5 µM	96.0	85.2	100	86.9	99.1	90.0	53.4

Primary screening of compounds 3, 4, 6 - 8, 10 on antiproliferative activity at concentration of 50.0  $\mu$ M.

Results are represented as the mean (n = 2); U251 = human glioblastoma; PC-3 = human prostate cancer; K562 = human chronic myelogenous leukemia; HCT-15 = human colon cancer; MCF-7 = human mammary adenocarcinoma; SKLU-1 = human lung adenocarcinoma; FGH = gingival human fibroblasts; NC = No cytotoxic. NT = No tested; \*Compounds tested at 1.0  $\mu$ M.

**Figure S48.** Primary screening of compounds **3**, **4**, **6** - **8**, **10** on antiproliferative activity at concentration of 50.0 µM.